Sign in
Stories
Rare Gastrointestinal Diseases Market Expansion
Share
89bio to Present pegozafermin for NASH a...
Advancements in Cancer Treatment and Mar...
Agilent's GenetiSure Dx Certification
AI-Powered Cancer Drug Trials
ANJESO Drug Insight and Market Forecast
Advancing OSE-279: Promising Cancer Trea...
Overview
API
The Rare Gastrointestinal Diseases Treatment Market is set to grow at a CAGR of 4.0%, reaching $2.63 billion by 2030. Key factors driving this growth include genomic sequencing, precision medicine, biologics and gene therapies, telemedicine, and AI-powered algorithms. Additionally, increasing disease awareness, advancements in medical research, rising healthcare expenditure, and government initiatives are contributing to market growth. Key players in the market include Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals, Shire (now part of Takeda), Amicus Therapeutics, Ipsen, and Sarepta Therapeutics.
Ask a question
How might the projected growth in the Rare Gastrointestinal Diseases Treatment Market impact the healthcare industry?
What potential advancements in technology could further drive the growth of this market?
What strategies could key players employ to address the challenges associated with the limited patient population and high development costs?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Oct 2023
Nov 2023
Dec 2023
Coverage